The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Nasal congestion treatments include drinking liquids, clearing out the nasal passages, and, when needed, using over-the-counter or prescription medication. These remedies will ease symptoms but may ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...

Alyssa Bauder was just learning how to read, but she had already memorized the colors of food packaging that spelled danger ...

(Reuters) -Upstream Bio, which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States. The drug ...

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

How Has Danaher Grown Over the Last Five Years?

As winter approaches, Mumbaikars are bracing for worse air quality, rising smog, and an increase in respiratory disorders.

Jeff Jacobson of 22V Research believes this is a strong signal for small-cap stocks, […] "Lorem ipsum dolor sit amet, ...

"While the families have acted lawfully in all respects, they sincerely regret that OxyContin, a prescription medicine that continues to help people suffering from chronic pain, unexpectedly ...